Lung Carcinoma

Oncology·MeSH: Small Cell Lung Carcinoma

25 drugs in development·11 companies·11 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
AZD2936	ASTRAZENECA PLC (AZN)
azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
MEDI4736+Tremelimumab	ASTRAZENECA PLC (AZN)
MK-4830	Merck & Co., Inc. (MRK)
open-label azd9291 80 mg/40 mg	ASTRAZENECA PLC (AZN)
osimertinib 80 mg/40 mg	ASTRAZENECA PLC (AZN)
Pemetrexed Disodium	ENANTA PHARMACEUTICALS INC (ENTA)
Topotecan	Merus N.V. (MRUS)

Phase 2(8)

Drug	Company
anlotinib	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
Budigalimab	AbbVie Inc. (ABBV)
erlotinib	CG Oncology, Inc. (CGON)
Montanide ISA 51 VG	ENANTA PHARMACEUTICALS INC (ENTA)
Montanide ISA 51 VG	Filana Therapeutics Inc. (FLNA)
Sargramostim	Filana Therapeutics Inc. (FLNA)
SVN53-67/M57-KLH Peptide Vaccine	Filana Therapeutics Inc. (FLNA)
tqb3616	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 1(6)

Drug	Company
111in-etn029	Novartis AG (NVS)
111in-etn029	NOVARTIS AG (NVSEF)
225ac-etn029	NOVARTIS AG (NVSEF)
225ac-etn029	Novartis AG (NVS)
BI 764532	Merus N.V. (MRUS)
EB-SELECT Single-Target CAR-NK Cells	Merus N.V. (MRUS)

Phase 2/Phase 3(1)

Drug	Company
Pemetrexed	AbbVie Inc. (ABBV)

Phase 4(2)

Drug	Company
bms-986489	BRISTOL MYERS SQUIBB CO (BMY)
Single agent chemotherapy	Merus N.V. (MRUS)

BioSniper tracks 25 drugs in development for Lung Carcinoma across 11 companies.

There are 11 clinical trials targeting Lung Carcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.